Novartis

Sales & Marketing
Q4 results roundup 2019

Q4 results roundup 2019

With the full year results season drawing to a close, Richard Staines asks who the winners were and who has been left playing catch-up.

News
Novartis licenses lipoprotein-lowering CVD drug

Novartis licenses lipoprotein-lowering CVD drug

Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ TQJ230, a treatment to reduce the risk of cardiovascular disease in people living with elev